NMRA Neumora Therapeutics, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1885522 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY19.4%
TTM EPS YoY27.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-252.7%
ROA-139.6%
ROIC (approx.)-332.4%
Asset turnover—
Leverage & solvency
Liabilities / assets80.5%
Debt / equity6.11x
Current ratio4.08x
Interest coverage-34.16x
Cash quality & payout
Operating cash flow / net income0.88x
Accruals ratio-16.9%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | — | — | — | — |
| R&D expense | $176.06M | $200.93M | $142.72M | $91.75M |
| SG&A expense | $60.09M | $62.54M | $45.48M | $31.12M |
| Operating income | -$241.16M | -$263.46M | -$252.10M | -$135.87M |
| Interest expense | $2.01M | $0 | — | — |
| Pretax income | -$236.80M | -$243.61M | -$235.66M | -$130.90M |
| Income tax | $130,000 | $178,000 | $268,000 | — |
| Net income | -$236.93M | -$243.79M | -$235.93M | -$130.90M |
| EBITDA | -$240.95M | -$262.83M | -$251.43M | -$135.28M |
| EPS (basic) | -1.45 | -1.53 | -3.63 | -4.81 |
| EPS (diluted) | -1.45 | -1.53 | -3.63 | -4.81 |
| Weighted avg. shares (diluted) | 163.39M | 159.38M | 65.02M | 27.21M |
| Balance sheet | ||||
| Cash & equivalents | $182.53M | $142.15M | $374.04M | $240.94M |
| Short-term investments | — | $165.43M | $79.94M | $130.94M |
| Current assets | $190.54M | $314.06M | $478.28M | $387.95M |
| PP&E, net | $40,000 | $1.14M | $1.79M | $2.41M |
| Total assets | $191.05M | $316.97M | $496.19M | $426.23M |
| Current liabilities | $32.45M | $29.89M | $25.11M | $23.70M |
| Short-term debt | $60.00M | — | — | — |
| Long-term debt | $54.53M | $0 | — | — |
| Total debt | $114.53M | $0 | — | — |
| Total liabilities | $87.18M | $29.91M | $27.12M | $29.40M |
| Shareholders' equity | $103.87M | $287.06M | $469.08M | -$446.85M |
| Net debt | -$68.00M | -$142.15M | — | — |
| Shares outstanding | 174.26M | 161.71M | 158.83M | 32.61M |
| Cash flow statement | ||||
| Operating cash flow | -$206.44M | -$182.94M | -$163.28M | -$114.90M |
| Capital expenditure | — | — | $117,000 | $511,000 |
| Free cash flow | — | — | -$163.40M | -$115.41M |
| Investing cash flow | $168.52M | -$70.56M | $64.39M | -$168.01M |
| Financing cash flow | $77.09M | $21.60M | $231.94M | $115.74M |
| Depreciation & amortization | $208,000 | $631,000 | $668,000 | $594,000 |
| Stock-based compensation | $29.88M | $39.99M | $17.24M | $8.30M |
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.